Palvella Therapeutics (NASDAQ:PVLA) Research Coverage Started at Chardan Capital

Chardan Capital assumed coverage on shares of Palvella Therapeutics (NASDAQ:PVLA) in a report issued on Wednesday, Marketbeat Ratings reports. The firm issued a buy rating and a $50.00 price target on the stock.

A number of other analysts have also weighed in on PVLA. Cantor Fitzgerald assumed coverage on shares of Palvella Therapeutics in a research note on Wednesday, December 18th. They issued an “overweight” rating for the company. Jones Trading started coverage on Palvella Therapeutics in a research note on Tuesday, March 25th. They set a “buy” rating and a $45.00 price target for the company. Stifel Nicolaus assumed coverage on Palvella Therapeutics in a research note on Wednesday, March 26th. They issued a “buy” rating and a $45.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and set a $38.00 target price on shares of Palvella Therapeutics in a research note on Tuesday, April 1st. Finally, TD Cowen started coverage on shares of Palvella Therapeutics in a research report on Wednesday, February 5th. They issued a “buy” rating and a $44.00 price target on the stock. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Palvella Therapeutics presently has an average rating of “Buy” and a consensus target price of $44.43.

Palvella Therapeutics Price Performance

Shares of PVLA opened at $21.76 on Wednesday. The firm has a market capitalization of $239.77 million, a price-to-earnings ratio of -1.80 and a beta of 0.10. The company’s fifty day simple moving average is $22.57. Palvella Therapeutics has a one year low of $6.20 and a one year high of $29.27.

Insider Buying and Selling

In other news, Director George M. Jenkins purchased 2,500 shares of Palvella Therapeutics stock in a transaction that occurred on Wednesday, April 9th. The stock was acquired at an average price of $20.13 per share, for a total transaction of $50,325.00. Following the transaction, the director now owns 183,171 shares in the company, valued at $3,687,232.23. The trade was a 1.38 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this link. 6.39% of the stock is currently owned by company insiders.

Institutional Trading of Palvella Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the business. BML Capital Management LLC acquired a new position in Palvella Therapeutics during the fourth quarter valued at $506,000. ADAR1 Capital Management LLC acquired a new position in shares of Palvella Therapeutics in the 4th quarter valued at about $1,736,000. Frazier Life Sciences Management L.P. acquired a new position in shares of Palvella Therapeutics in the 4th quarter valued at about $7,847,000. Cresset Asset Management LLC purchased a new stake in shares of Palvella Therapeutics in the fourth quarter worth approximately $251,000. Finally, Suvretta Capital Management LLC acquired a new stake in shares of Palvella Therapeutics during the fourth quarter worth approximately $8,574,000. Institutional investors and hedge funds own 40.11% of the company’s stock.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.